Callan Family Office LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 24,836 shares of the medical research company's stock, valued at approximately $2,247,000.
A number of other hedge funds have also recently added to or reduced their stakes in EW. Keating Financial Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter worth about $39,000. Allworth Financial LP purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $1,502,000. B. Metzler seel. Sohn & Co. AG acquired a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $3,777,000. TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $27,000. Finally, Fairtree Asset Management Pty Ltd acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $2,383,000. Hedge funds and other institutional investors own 79.46% of the company's stock.
Wall Street Analysts Forecast Growth
EW has been the topic of a number of research analyst reports. Evercore reiterated an "outperform" rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Piper Sandler reiterated an "overweight" rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $100.27.
View Our Latest Research Report on EW
Insiders Place Their Bets
In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm's stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company's stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,570 shares of company stock valued at $2,219,390 in the last quarter. 0.31% of the stock is currently owned by company insiders.
Edwards Lifesciences Stock Performance
Shares of NYSE EW opened at $89.89 on Friday. The company has a 50-day simple moving average of $89.21 and a 200-day simple moving average of $84.67. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company has a market cap of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Edwards Lifesciences Profile
(
Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
